1061353-68-1 | Pnd-1186

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$25.00	$17.00
2mg	95%	in stock	$30.00	$21.00
5mg	95%	in stock	$38.00	$26.00
10mg	95%	in stock	$49.00	$34.00
50mg	95%	in stock	$118.00	$82.00
100mg	95%	in stock	$188.00	$131.00
250mg	95%	in stock	$376.00	$263.00
1g	95%	in stock	$780.00	$546.00

Description

• Catalog Number: AE11319
• Chemical Name: Pnd-1186
• CAS Number: 1061353-68-1
• Molecular Formula: C25H26F3N5O3
• Molecular Weight: 501.5008
• MDL Number: MFCD28125506
• SMILES: CNC(=O)c1ccccc1Nc1cc(ncc1C(F)(F)F)Nc1ccc(cc1OC)N1CCOCC1

Computed Properties

• Complexity: 709
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 4.7

Upstream Synthesis Route

PND-1186 is a potent and selective inhibitor of focal adhesion kinase (FAK), a key regulator of cell migration, proliferation, and survival processes. In chemical synthesis, PND-1186 plays a crucial role in inhibiting the activity of FAK signaling pathways, thereby affecting the dynamics of cellular adhesion and migration. By specifically targeting FAK, PND-1186 offers a valuable tool for researchers and chemists studying cell biology, cancer biology, and drug development. This compound can be utilized to explore the mechanisms underlying FAK-mediated pathways, opening new opportunities for designing novel therapeutic agents that target FAK in various diseases. Additionally, PND-1186's high specificity and potency make it a valuable tool in understanding the intricate interplay between cellular signaling pathways, offering insights that can inform the development of targeted therapies with potential applications in cancer treatment and beyond.

Literature

• FAK signaling in human cancer as a target for therapeutics.

  Pharmacology & therapeutics 20150201

• FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

  Molecular cancer therapeutics 20140801

• PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

  Cancer biology & therapy 20100501

• Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

  Cancer biology & therapy 20100501